| Year |
Title |
Altmetric |
| 2022
|
Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
Clinical Cancer Research.
28:5419-5430.
2022
|
|
| 2022
|
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Neuro-Oncology.
24:1964-1975.
2022
|
|
| 2022
|
Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Pharmacology and Therapeutics.
239.
2022
|
|
| 2022
|
Machine Learning in the Classification of Pediatric Posterior Fossa Tumors: A Systematic Review.
Cancers.
14.
2022
|
|
| 2022
|
Targeting oncometabolism to maximize immunotherapy in malignant brain tumors.
Oncogene.
41:2663-2671.
2022
|
|
| 2022
|
Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.
Cancers.
14.
2022
|
|
| 2022
|
Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy.
Cancers.
14.
2022
|
|
| 2022
|
Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
International Journal of Molecular Sciences.
23.
2022
|
|
| 2022
|
Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing.
NOA.
4.
2022
|
|
| 2022
|
Immunotherapy approaches for the treatment of diffuse midline gliomas.
OncoImmunology.
11.
2022
|
|
| 2022
|
Standard clinical approaches and emerging modalities for glioblastoma imaging.
NOA.
4.
2022
|
|
| 2021
|
Potential role of carbon ion radiotherapy in chromothripsis-induced medulloblastoma and other malignancies.
Neuro-Oncology.
23:1991-1992.
2021
|
|
| 2021
|
Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma.
Pediatric Blood and Cancer.
68.
2021
|
|
| 2021
|
Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas.
New England Journal of Medicine.
384:1613-1622.
2021
|
|
| 2021
|
Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
Neurosurgery Clinics of North America.
32:265-281.
2021
|
|
| 2021
|
Integrin αvβ3 engagement regulates glucose metabolism and migration through focal adhesion kinase (Fak) and protein arginine methyltransferase 5 (prmt5) in glioblastoma cells.
Cancers.
13:1-16.
2021
|
|
| 2021
|
Therapeutic cancer vaccines for pediatric malignancies: Advances, challenges, and emerging technologies.
NOA.
3.
2021
|
|
| 2020
|
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Human gene therapy. Clinical development.
31:1132-1139.
2020
|
|
| 2020
|
Intraventricular metastatic melanoma: A case report and review of the literature.
Clinical Case Reports.
8:1757-1764.
2020
|
|
| 2020
|
Roseomonas gilardii Bacteremia in a Patient with HbSβ0-thalassemia: Clinical Implications and Literature Review.
Journal of Pediatric Hematology/Oncology.
42:e385-e387.
2020
|
|
| 2020
|
Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.
Cancer Gene Therapy.
27:246-255.
2020
|
|
| 2020
|
Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience.
Pediatric Blood and Cancer.
67.
2020
|
|
| 2020
|
An update on neurofibromatosis type 1-associated gliomas.
Cancers.
12.
2020
|
|
| 2020
|
Glioma stem cells and their roles within the hypoxic tumor microenvironment.
Theranostics.
11:665-683.
2020
|
|
| 2019
|
A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.
OncoImmunology.
8.
2019
|
|
| 2019
|
Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread.
Clinical Case Reports.
7:2341-2345.
2019
|
|
| 2019
|
UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts.
Translational Oncology.
12:1364-1374.
2019
|
|
| 2019
|
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance.
Oncogene.
38:6159-6171.
2019
|
|
| 2019
|
The Impact of Early Corticosteroid Pretreatment before Initiation of Chemotherapy in Patients with Primary Central Nervous System Lymphoma.
Neurosurgery.
85:264-272.
2019
|
|
| 2019
|
SUMOylation in glioblastoma: A novel therapeutic target.
International Journal of Molecular Sciences.
20.
2019
|
|
| 2019
|
SUMOylation promotes survival and integration of neural stem cell grafts in ischemic stroke.
EBioMedicine.
42:214-224.
2019
|
|
| 2019
|
Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors.
World Neurosurgery.
122:e1592-e1598.
2019
|
|
| 2019
|
Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis.
Journal of Neuro-Oncology.
141:289-301.
2019
|
|
| 2019
|
Artificial intelligence in the management of glioma: Era of personalized medicine.
Frontiers in Oncology.
9.
2019
|
|
| 2019
|
Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1.
Journal of Clinical Oncology.
37:3050-3058.
2019
|
|
| 2019
|
Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with charcot–marie–tooth disease
2019
|
|
| 2018
|
Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
Scientific Reports.
8.
2018
|
|
| 2018
|
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.
Scientific Reports.
8.
2018
|
|
| 2018
|
UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.
Journal of Neuro-Oncology.
140:209-224.
2018
|
|
| 2018
|
Drugging SUMOylation for neuroprotection and oncotherapy.
Neural Regeneration Research.
13:415-416.
2018
|
|
| 2018
|
Cerebral ischemia increases small ubiquitin-like modifier conjugation within human penumbral tissue: Radiological-pathological correlation.
Frontiers in Neurology.
8.
2018
|
|
| 2018
|
Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia.
2018
|
|
| 2017
|
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002
2017
|
|
| 2017
|
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Pediatric Blood and Cancer.
64.
2017
|
|
| 2017
|
Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.
American Journal of Hematology.
92:E81-E83.
2017
|
|
| 2017
|
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Neurotherapeutics.
14:333-344.
2017
|
|
| 2017
|
Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Human gene therapy. Clinical development.
28:7-16.
2017
|
|
| 2017
|
Checkpoint proteins in pediatric brain and extracranial solid tumors: Opportunities for immunotherapy.
Clinical Cancer Research.
23:342-350.
2017
|
|
| 2017
|
Combination strategies enhance oncolytic virotherapy.
Oncotarget.
8:34020-34021.
2017
|
|
| 2016
|
Protocol for Reducing Time to Antibiotics in Pediatric Patients Presenting to an Emergency Department with Feer and Neutropenia: Efficacy and Barriers.
Pediatric Emergency Care.
32:739-745.
2016
|
|
| 2016
|
Effect of repeat dosing of engineered oncolytic herpes simplex virus on preclinical models of rhabdomyosarcoma.
Translational Oncology.
9:419-430.
2016
|
|
| 2016
|
Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Neuro-Oncology.
18:227-235.
2016
|
|
| 2016
|
Oncolytic virotherapy for pediatric malignancies: future prospects..
Oncolytic Virotherapy.
5:73-80.
2016
|
|
| 2015
|
Pediatric cancer gone viral. Part I: Strategies for utilizing oncolytic herpes simplex virus-1 in children
2015
|
|
| 2015
|
Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in children
2015
|
|
| 2015
|
Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.
Journal of Neuro-Oncology.
122:585-593.
2015
|
|
| 2015
|
Attack of the cancer-killing viruses: Clinical application of oncolytic virotherapy in children.
Pediatric Blood and Cancer.
62:739-740.
2015
|
|
| 2015
|
γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia
2015
|
|
| 2014
|
Oncolytic viral therapy: targeting cancer stem cells..
Oncolytic Virotherapy.
2014:21-33.
2014
|
|
| 2014
|
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.
PLoS One.
9.
2014
|
|
| 2014
|
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Journal of Neuro-Oncology.
118:61-72.
2014
|
|
| 2014
|
The role of Src family kinases in growth and migration of glioma stem cells.
International Journal of Oncology.
45:302-310.
2014
|
|
| 2013
|
Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapy.
Frontiers in Oncology.
3 FEB.
2013
|
|
| 2013
|
Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma.
PLoS One.
8.
2013
|
|
| 2013
|
Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Journal of Pediatric Hematology/Oncology.
35.
2013
|
|
| 2013
|
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
Pediatric Blood and Cancer.
60:45-52.
2013
|
|
| 2012
|
Hypoxia moderates γ134.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary cultures.
Translational Oncology.
5:200-207.
2012
|
|
| 2012
|
Targeting pediatric cancer stem cells with oncolytic virotherapy..
Pediatric Research.
71:500-510.
2012
|
|
| 2011
|
Response to radiation in renal medullary carcinoma.
Rare Tumors.
3:100-103.
2011
|
|
| 2011
|
Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosis.
Pediatric Blood and Cancer.
57:180-181.
2011
|
|
| 2011
|
Cancer stem cells and pediatric solid tumors.
Cancers.
3:298-318.
2011
|
|
| 2010
|
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
Pediatric Blood and Cancer.
55:1217-1220.
2010
|
|
| 2009
|
Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
Journal of Neuro-Oncology.
95:199-209.
2009
|
|
| 2009
|
Herpes simplex virus oncolytic therapy for pediatric malignancies.
Molecular Therapy.
17:1125-1135.
2009
|
|
| 2008
|
Myelofibrosis in a patient with familial hemophagocytic lymphohistiocytosis.
Pediatric Blood and Cancer.
50:1260-1262.
2008
|
|
| 2007
|
Changing trends of research and treatment in infant neuroblastoma.
Pediatric Blood and Cancer.
49:1060-1065.
2007
|
|
